MARKET

WVE

WVE

Wave Life Scienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.230
-0.040
-3.15%
Closed 16:00 05/20 EDT
OPEN
1.290
PREV CLOSE
1.270
HIGH
1.290
LOW
1.200
VOLUME
199.96K
TURNOVER
--
52 WEEK HIGH
7.55
52 WEEK LOW
1.160
MARKET CAP
75.34M
P/E (TTM)
-0.5772
1D
5D
1M
3M
1Y
5Y
Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences
RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental. 
Benzinga · 05/13 18:51
Wave Life Sciences slips as H.C. Wainwright lowers target
Then shares of Wave Life Sciences (NASDAQ:WVE) are trading lower in the morning hours Friday after H.C. Wainwright trimmed the price target of the clinical-stage genetic medicine company citing a
Seekingalpha · 05/13 14:18
Inotiv, TScan Therapeutics top healthcare gainers; Opiant, Renovacor lead losers' pack
Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. PetIQ (PETQ) ...
Seekingalpha · 05/13 14:07
--SVB Securities Adjusts Price Target on WAVE Life Sciences to $3 From $7, Maintains Market Perform Rating
MT Newswires · 05/13 09:35
--HC Wainwright Adjusts WAVE Life Sciences' Price Target to $8 from $10, Keeps Buy Rating
MT Newswires · 05/13 09:09
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 53.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 12:45
Recap: WAVE Life Sciences Q1 Earnings
  WAVE Life Sciences (NASDAQ:WVE) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 11:46
BRIEF-WAVE Life Sciences Reports Q1 Revenue Of $1.8 Mln
reuters.com · 05/12 11:43
More
No Data
Learn about the latest financial forecast of WVE. Analyze the recent business situations of Wave Life Scienc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
42.86%Buy
42.86%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average WVE stock price target is 8.57 with a high estimate of 17.00 and a low estimate of 3.000.
High17.00
Average8.57
Low3.000
Current 1.230
EPS
Actual
Estimate
-0.62-0.47-0.31-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 132
Institutional Holdings: 64.94M
% Owned: 106.02%
Shares Outstanding: 61.25M
TypeInstitutionsShares
Increased
21
3.49M
New
7
107.94K
Decreased
33
1.58M
Sold Out
15
1.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Christian Henry
President/Chief Executive Officer/Director
Paul Bolno
Chief Financial Officer
Kyle Moran
Senior Vice President
Christopher Francis
Chief Technology Officer
Chandra Vargeese
Other
Michael Panzara
Director
Gregory Verdine
Independent Director
Mark Corrigan
Independent Director
Peter Kolchinsky
Independent Director
Adrian Rawcliffe
Independent Director
Ken Takanashi
Independent Director
Aik Na Tan
Independent Director
Heidi Wagner
No Data
No Data
About WVE
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company engaged in delivering life-changing treatments for people battling devastating diseases. The Company is developing oligonucleotides, which targets ribonucleic acid (RNA) to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Using PRISM, its own discovery and drug development platform, which enables the precise design, optimization and production of stereopure oligonucleotides, it aspires to develop medicines for genetically defined diseases with a degree of unmet need. By intervening at the RNA level, it has the potential to address diseases with small molecules or biologics, while retaining the ability to titrate dose and avoid permanent off-target genetic changes and other challenges associated with DNA editing or gene therapy approaches.

Webull offers kinds of Wave Life Sciences Ltd stock information, including NASDAQ:WVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading WVE stock methods without spending real money on the virtual paper trading platform.